Our recent game-changing investments include:

**Preventive treatments**
Protection for pregnant women in sub-Saharan Africa and rainy season prevention for small children in the Sahel region

$120 m

**Vaccine**
Piloting the world’s first malaria vaccine in three high-malaria countries in Africa

$10 m

**Treatment**
Expanding access to injectable artesunate for children with severe malaria, and to rectal artesunate as an emergency measure

$53 m

**Vector control tools**
Protecting families with new-generation bed nets and indoor sprays, mosquito-repellent sheets for refugee camps, and a drug for humans and livestock that kills mosquitoes

$190 m

**Diagnosis**
Establishing quality control and increasing the use of rapid diagnostic tests for malaria

$44 m

**Our portfolio keeps growing**
Upcoming investments will support fever management and the fight against Plasmodium vivax malaria, and we will continue to provide funding for WHO’s prequalification program

$400 m

Unitaid’s malaria portfolio has doubled during 2015-2018 and will continue to expand through 2020